globenewswire.com

Neurocrine Receives FDA IND Acceptance for Phase 2 Alzheimer Study of NBI-1117567

Neurocrine Biosciences logoNeurocrine Biosciences
Sig2.59Sen+3.75Env0.00Soc+0.65Gov+0.60
Nxera Pharma logoNxera Pharma
Sig2.55Sen+6.10Env0.00Soc0.00Gov0.00

Neurocrine Biosciences received U.S. FDA IND acceptance for a Phase 2 study of NBI-1117567 for Alzheimer’s cognition. The oral muscarinic M1 preferring agonist is being advanced through a multi-program collaboration with Nxera, which retains development and commercialization rights for M1 agonists in Japan. Neurocrine is responsible for global development costs and will make a US$10 million IND acceptance milestone payment to Nxera.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro